Mynvax, IIsc-incubated startup looks at Covid-19 vaccine in 18 months

The startup, incubated at the Indian Institute of Science, Bengaluru, also said it was critical to build capability to produce the vaccine in large numbers. The IISc-Mynvax team is among more than two dozen teams in India working on a vaccine to ...

Reuters
Representative Image
BENGALURU: Mynvax, a startup that is developing a homegrown vaccine to prevent Covid-19 infections, expects a safe and efficacious one to be ready in about 18 months.

The startup, incubated at the Indian Institute of Science, Bengaluru, also said it was critical to build capability to produce the vaccine in large numbers.

“We also need to have technologies and facilities that can produce several hundreds of millions of doses of the vaccine to protect those most in need,” Raghavan Varadarajan, co-founder of Mynvax and a professor at the Molecular Biophysics Unit, told ET.


The IISc-Mynvax team is among more than two dozen teams in India working on a vaccine to combat the outbreak that has disrupted societies across the globe.

Several research teams from IIT-Guwahati, Indian Institute of Chemical Technology, CMC Vellore and private firms such as Zydus Cadilla, Biological E, Auro Pharma, Bharat Biotech and Serum Institute are in various stages of developing the vaccine, both locally as well as in collaboration with global organisations.

Mynvax has developed several candidate immunogens and completed initial animal trials.
ADVERTISEMENT

“We are working on multiple new molecules for which we will have animal data in the next few months,” Varadarajan said. “These are sub unit-based vaccines. It requires testing in animals before we go to humans. We also need to look at efficacy, cost of production and scalability.”

Untitled1

He added that there needs to be multiple vaccine candidates as the virus is likely to be around for some time. "It is unclear at this time what the best candidates would be."

Mynvax has applied for Rs 15 crore in funding from the Biotechnology Industry Research Assistance Council (BIRAC) to scale up the process.

ADVERTISEMENT
Previous studies have shown that antibodies against the spike glycoprotein found on the surface of the earlier 2003 SARS-CoV virus inhibit viral infection in cell culture and confer protection against infection in animal models.

Hence, Mynvax and others are attempting to design and test variants of the spike glycoprotein of SARS-CoV-2 (Covid-19) as vaccine candidates, its researchers wrote in a summary of their project.

ADVERTISEMENT
"There are spike proteins on the virus. It binds to receptors called the Ace2receptors," Varadarajan said. "We and others are developing various derivatives of the viral spike protein as vaccinecandidates that will induce protective anti-bodies."
Download
The Economic Times Business News App
for the Latest News in Business, Sensex, Stock Market Updates & More.
READ MORE
ADVERTISEMENT

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

More from our Partners

Loading next story
Text Size:AAA
Success
This article has been saved

*

+